Note: By writing this post, we are not recommending this drug. Some of our readers who were already taking the drug requested that we commission a post on it, and we are simply providing information that is available in the scientific literature. Please discuss your medications with your doctor. Myo-Inositol Trispyrophosphate is specifically a drug that we at SelfHacked would recommend against.
What is Myo-Inositol Trispyrophosphate?
Myo-Inositol Trispyrophosphate (ITPP) is an allosteric effector of hemoglobin that increases red blood cells’ ability to release oxygen. This means it increases red blood cells’ ability to release oxygen by binding to another site than the active site where oxygen binds [R].
Oxygen delivery is important for maximal muscle function and activity.
ITPP is able to cross the red blood cell membrane [R].
ITPP is a synthetic compound derived from myoinositol hexakisphosphate, which is normally produced in mammalian cells and has antioxidant and anti-cancer properties [R].
Uses of Myo-Inositol Trispyrophosphate
ITPP’s ability to improve oxygen carrying capacity and delivery makes it a great candidate to decrease hypoxia. Hypoxia is the deficiency in oxygen delivery to tissues and it normally encourages angiogenesis (the development of new blood vessels) as well as cancer progression [R].
Hypoxia is bad because tumors with low oxygen levels induce the formation of new blood vessels. This process occurs when Hypoxia-inducible genes, such as VEGF are switched on. Then, human Microvascular Endothelial Cells line up to begin angiogenesis [R].
ITPP blocks the Microvascular Endothelial Cells from lining up because ITPP allows the red blood cells to carry and release enough oxygen to suppress/prevent hypoxic conditions [R].
More oxygen is released at low oxygen tissue [R].
The effects lasted for the same amount of time as the half-life of a red blood cell, showing that the effects last for a long time [R].
2) Exercise Capacity
ITPP decreases oxygen binding to red blood cells, thus increasing oxygen release to blood [R].
Mice with heart problems were injected with ITPP. Their red blood cells were able to carry about 22% more oxygen than normal mice [R].
ITPP suppresses HIF, indicating that ITPP does increase the availability of oxygen to tissue [R].
It increased the exercise capacity of the mice, due to increased oxygen delivery. This indicates that ITPP can help improve exercise capacity in patients who have suffered from heart failure [R].
ITPP was also able to increase oxygen-carrying capacity and delivery in the hemoglobin of normal mice.
Mice were tested using a treadmill before and after ITPP injection. ITPP did increase their exercise capacity [R].
A side-effect of Pancreatic Cancer is hypoxia, which leads to chemotherapy resistance and immune system suppression [R].
A study was performed to determine if ITPP can improve normal oxygen function, thus improving the chemotherapy response. Weekly intravenous ITPP injection decreased metastases and tumor growth. Normal oxygen function in the tumor returned and hypoxia decreased [R].
This also led to better immune cell function and better response to chemotherapy [R].
Normal oxygen function was achieved because ITPP normalized the generation of new blood vessels and vascularization [R].
ITPP improved survival rates for mice with colon cancer by decreasing the spread of cancer cells and stimulating the expression of the Cdx2 gene, which is usually decreased in tumors due to hypoxia [R].
ITPP enhances the capacity of hemoglobin to release bound oxygen, thus inhibiting hypoxia-induced angiogenesis [R].
Preventing tumor neovascularization is a beneficial treatment to halt the spread of cancer cells and metastases [R].
Athletes may use ITPP because it increases exercise capacity. However, this is a type of doping. ITPP is banned in professional sports [R].
Check out Lab Test Analyzer!
Get personalized up-to-date science-backed lifestyle, diet, and supplement recommendations based on your lab tests!